Barrington Research Raises Earnings Estimates for Surmodics

Key Points

• Barrington Research has raised its FY2025 earnings per share estimate for Surmodics to ($0.30) from a previous estimate of ($0.57), while maintaining a "Market Perform" rating on the stock.
• Surmodics reported Q2 earnings of $0.06 per share, significantly beating analyst estimates of ($0.21) and achieving revenues of $29.57 million compared to a consensus of $28.04 million.
• Institutional investors hold a dominant stake in Surmodics, owning 96.63% of the company's shares, with several hedge funds recently increasing their positions.

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Stock analysts at Barrington Research upped their FY2025 earnings per share estimates for shares of Surmodics in a note issued to investors on Monday, August 11th. Barrington Research analyst M. Petusky now expects that the company will post earnings per share of ($0.30) for the year, up from their prior estimate of ($0.57). Barrington Research currently has a "Market Perform" rating on the stock. The consensus estimate for Surmodics' current full-year earnings is $0.20 per share. Barrington Research also issued estimates for Surmodics' Q4 2025 earnings at ($0.19) EPS and FY2026 earnings at ($0.12) EPS.

Surmodics (NASDAQ:SRDX - Get Free Report) last announced its quarterly earnings results on Friday, August 8th. The company reported $0.06 EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.27. The business had revenue of $29.57 million for the quarter, compared to analysts' expectations of $28.04 million. Surmodics had a negative return on equity of 2.99% and a negative net margin of 14.59%.

A number of other brokerages have also recently commented on SRDX. Needham & Company LLC reaffirmed a "hold" rating on shares of Surmodics in a research note on Wednesday, April 30th. Zacks Research raised Surmodics to a "hold" rating in a research note on Tuesday, August 12th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $43.00.

Surmodics Trading Down 1.5%

Surmodics stock traded down $0.57 during trading hours on Wednesday, reaching $36.89. The company had a trading volume of 509,864 shares, compared to its average volume of 183,011. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.91 and a quick ratio of 3.10. The company has a 50-day moving average price of $32.08 and a 200 day moving average price of $30.82. The firm has a market cap of $527.53 million, a price-to-earnings ratio of -29.99 and a beta of 1.31. Surmodics has a 12-month low of $26.00 and a 12-month high of $40.38.

Hedge Funds Weigh In On Surmodics

Several hedge funds have recently made changes to their positions in SRDX. JPMorgan Chase & Co. increased its stake in shares of Surmodics by 20.1% during the fourth quarter. JPMorgan Chase & Co. now owns 50,990 shares of the company's stock valued at $2,019,000 after buying an additional 8,520 shares during the period. Wells Fargo & Company MN increased its stake in shares of Surmodics by 40.9% during the fourth quarter. Wells Fargo & Company MN now owns 7,032 shares of the company's stock valued at $278,000 after buying an additional 2,041 shares during the period. Legal & General Group Plc increased its stake in shares of Surmodics by 34.2% during the fourth quarter. Legal & General Group Plc now owns 3,452 shares of the company's stock valued at $137,000 after buying an additional 880 shares during the period. Barclays PLC increased its stake in shares of Surmodics by 21.7% during the fourth quarter. Barclays PLC now owns 108,001 shares of the company's stock valued at $4,278,000 after buying an additional 19,251 shares during the period. Finally, Gabelli Funds LLC increased its stake in shares of Surmodics by 3.7% during the fourth quarter. Gabelli Funds LLC now owns 339,959 shares of the company's stock valued at $13,462,000 after buying an additional 12,250 shares during the period. 96.63% of the stock is owned by hedge funds and other institutional investors.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).